1
|
Cruz P, Bortoli JD, Benalcázar-Jalkh EB, Boutros SM, Bhola M, Grande F, Nayak VV, Tovar N, Coelho PG, Witek L. Atypical histological presentation of bone regeneration after insertion of cryoprotected allogeneic bone graft. Med Oral Patol Oral Cir Bucal 2024; 29:e103-e110. [PMID: 37992144 PMCID: PMC10765327 DOI: 10.4317/medoral.26094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Accepted: 09/05/2023] [Indexed: 11/24/2023] Open
Abstract
BACKGROUND To evaluate bone regenerative capacity of cryoprotected corticocancellous allogeneic bone graft performed in type II and III post-extraction sockets for ridge preservation after twelve weeks in-vivo. MATERIAL AND METHODS Twenty-seven type II or III bony-walled extraction sockets (mandible and maxilla) were selected for this study. Following atraumatic tooth-extraction a cryoprotected corticocancellous allogeneic bone graft material and a resorbable porcine-derived collagen membrane were used for ridge preservation. During re-entry surgery at approximately 12 weeks, bone core biopsies were obtained using a 3.2 mm trephine drill and samples were histologically processed and subjected to qualitative and quantitative histomorphometric analysis. Quantitative data was analyzed using a general linear mixed model with results presented as mean values with the corresponding 95% confidence interval values. RESULTS Healing without incident and ridge preservation allowed for the placement of dental implants after 12 weeks in 25 out of the 27 treated socket sites. Analyses yielded an average of ~21.0±7% of old/native bone, ~17±5.5% of newly regenerated bone (total of ~38±12.8% for all bone), 0.23±0.14% of new bone presenting with nucleating sites within the matrix, ~52±5.12% of soft tissue, and 3.6±2.09% of damaged bone. The average regenerated bone was statistically analogous to that of old/native bone (p=0.355). Furthermore, an atypical histological pattern of bone regeneration was observed, with newly formed bone exhibiting "infiltration-like" behavior and with new bone nucleating sites observed within the demineralized bone matrix. CONCLUSIONS Cryoprotected corticocancellous allogeneic bone-graft demonstrated osteoconductive, osteoinductive, and osteogenic properties, yielding unique healing patterns which does warrant further investigation.
Collapse
Affiliation(s)
- P Cruz
- Biomaterials Division New York University College of Dentistry 345 E. 24th St, Room 902D 10010, New York, NY, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Garutti I, Cabañero A, Vicente R, Sánchez D, Granell M, Fraile CA, Real Navacerrada M, Novoa N, Sanchez-Pedrosa G, Congregado M, Gómez A, Miñana E, Piñeiro P, Cruz P, de la Gala F, Quero F, Huerta LJ, Rodríguez M, Jiménez E, Puente-Maestu L, Aragon S, Osorio-Salazar E, Sitges M, Lopez Maldonado MD, Rios FT, Morales JE, Callejas R, Gonzalez-Bardancas S, Botella S, Cortés M, Yepes MJ, Iranzo R, Sayas J. Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program. Rev Esp Anestesiol Reanim (Engl Ed) 2022; 69:208-241. [PMID: 35585017 DOI: 10.1016/j.redare.2021.02.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Accepted: 02/04/2021] [Indexed: 06/15/2023]
Abstract
In recent years, multidisciplinary programs have been implemented that include different actions during the pre, intra and postoperative period, aimed at reducing perioperative stress and therefore improving the results of patients undergoing surgical interventions. Initially, these programs were developed for colorectal surgery and from there they have been extended to other surgeries. Thoracic surgery, considered highly complex, like other surgeries with a high postoperative morbidity and mortality rate, may be one of the specialties that most benefit from the implementation of these programs. This review presents the recommendations made by different specialties involved in the perioperative care of patients who require resection of a lung tumor. Meta-analyzes, systematic reviews, randomized and non-randomized controlled studies, and retrospective studies conducted in patients undergoing this type of intervention have been taken into account in preparing the recommendations presented in this guide. The GRADE scale has been used to classify the recommendations, assessing on the one hand the level of evidence published on each specific aspect and, on the other hand, the strength of the recommendation with which the authors propose its application. The recommendations considered most important for this type of surgery are those that refer to pre-habilitation, minimization of surgical aggression, excellence in the management of perioperative pain and postoperative care aimed at providing rapid postoperative rehabilitation.
Collapse
Affiliation(s)
- I Garutti
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
| | - A Cabañero
- Servicio de Cirugía Torácica, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - R Vicente
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, Spain
| | - D Sánchez
- Servicio de Cirugía Torácica, Hospital Clínic, Barcelona, Spain
| | - M Granell
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, Spain
| | - C A Fraile
- Servicio de Cirugía Torácica, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - M Real Navacerrada
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - N Novoa
- Servicio de Cirugía Torácica, Complejo Asistencial Universitario de Salamanca (CAUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
| | - G Sanchez-Pedrosa
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - M Congregado
- Servicio de Cirugía Torácica, Hospital Virgen de la Macarena, Sevilla, Spain
| | - A Gómez
- Unitat de Rehabilitació Cardiorespiratòria, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - E Miñana
- Servicio de Anestesia y Reanimación, Hospital de la Ribera, Alzira, Valencia, Spain
| | - P Piñeiro
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - P Cruz
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - F de la Gala
- Servicio Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - F Quero
- Servicio de Cirugía Torácica, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - L J Huerta
- Servicio de Cirugía Torácica, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - M Rodríguez
- Servicio de Cirugía Torácica, Clínica Universidad de Navarra, Madrid, Spain
| | - E Jiménez
- Fisioterapia Respiratoria, Hospital Universitario A Coruña, La Coruña, Spain
| | - L Puente-Maestu
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | - S Aragon
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, Spain
| | - E Osorio-Salazar
- Servicio de Anestesia y Reanimación, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - M Sitges
- Bloc Quirúrgic i Esterilització, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
| | | | - F T Rios
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, Spain
| | - J E Morales
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, Spain
| | - R Callejas
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, Spain
| | - S Gonzalez-Bardancas
- Servicio de Anestesia y Reanimación, Complejo Hospitalario Universitario A Coruña, La Coruña, Spain
| | - S Botella
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, Spain
| | - M Cortés
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M J Yepes
- Servicio de Anestesia y Reanimación, Clínica Universidad de Navarra, Navarra, Pamplona, Spain
| | - R Iranzo
- Servicio de Anestesia y Reanimación, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - J Sayas
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| |
Collapse
|
3
|
Di Bitetti MS, Iezzi ME, Cruz P, Cirignoli S, Varela D, De Angelo C. Enemies or good neighbors? No indication of spatial or temporal avoidance between two sympatric South
American canids. J Zool (1987) 2022. [DOI: 10.1111/jzo.12965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Affiliation(s)
- M. S. Di Bitetti
- Instituto de Biología Subtropical (IBS) Universidad Nacional de Misiones (UNaM) ‐ CONICET Puerto Iguazú Argentina
- Asociación Civil Centro de Investigaciones del Bosque Atlántico Puerto Iguazú Argentina
- Facultad de Ciencias Forestales UNaM Eldorado Argentina
| | - M. E. Iezzi
- Instituto de Biología Subtropical (IBS) Universidad Nacional de Misiones (UNaM) ‐ CONICET Puerto Iguazú Argentina
- Asociación Civil Centro de Investigaciones del Bosque Atlántico Puerto Iguazú Argentina
| | - P. Cruz
- Instituto de Biología Subtropical (IBS) Universidad Nacional de Misiones (UNaM) ‐ CONICET Puerto Iguazú Argentina
- Asociación Civil Centro de Investigaciones del Bosque Atlántico Puerto Iguazú Argentina
- Facultad de Ciencias Forestales UNaM Eldorado Argentina
| | - S. Cirignoli
- Asociación Civil Centro de Investigaciones del Bosque Atlántico Puerto Iguazú Argentina
| | - D. Varela
- Instituto de Biología Subtropical (IBS) Universidad Nacional de Misiones (UNaM) ‐ CONICET Puerto Iguazú Argentina
- Asociación Civil Centro de Investigaciones del Bosque Atlántico Puerto Iguazú Argentina
| | - C. De Angelo
- Asociación Civil Centro de Investigaciones del Bosque Atlántico Puerto Iguazú Argentina
- Instituto de Ciencias de la Tierra Biodiversidad y Ambiente (ICBIA) Universidad Nacional de Río Cuarto (UNRC) – CONICET Río Cuarto Argentina
| |
Collapse
|
4
|
Obispo B, Hernandez R, Cruz P, Fernandez Montes A, Gil Raga M, Garcia O, Rogado J, Asensio-Martinez E, Piera Molons N, Pacheco-Barcia V, López de Ceballos M, Cano J, Ostios Garcia L, Antoñanzas Basa M, Lorente D, Manzano Fernández A, Hernando Polo S, Gonzalez Moya M, Garcia T, Calderon C. 1494P Anxiety and depression during the COVID-19 pandemic in newly diagnosed advanced cancer patients. Ann Oncol 2021. [PMCID: PMC8454355 DOI: 10.1016/j.annonc.2021.08.822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Garutti I, Cabañero A, Vicente R, Sánchez D, Granell M, Fraile CA, Real Navacerrada M, Novoa N, Sanchez-Pedrosa G, Congregado M, Gómez A, Miñana E, Piñeiro P, Cruz P, de la Gala F, Quero F, Huerta LJ, Rodríguez M, Jiménez E, Puente-Maestu L, Aragon S, Osorio-Salazar E, Sitges M, Lopez Maldonado MD, Rios FT, Morales JE, Callejas R, Gonzalez-Bardancas S, Botella S, Cortés M, Yepes MJ, Iranzo R, Sayas J. Recommendations of the Society of Thoracic Surgery and the Section of Cardiothoracic and Vascular Surgery of the Spanish Society of Anesthesia, Resuscitation and Pain Therapy, for patients undergoing lung surgery included in an intensified recovery program. Rev Esp Anestesiol Reanim (Engl Ed) 2021; 69:S0034-9356(21)00102-X. [PMID: 34294445 DOI: 10.1016/j.redar.2021.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 01/28/2021] [Accepted: 02/04/2021] [Indexed: 11/24/2022]
Abstract
In recent years, multidisciplinary programs have been implemented that include different actions during the pre, intra and postoperative period, aimed at reducing perioperative stress and therefore improving the results of patients undergoing surgical interventions. Initially, these programs were developed for colorectal surgery and from there they have been extended to other surgeries. Thoracic surgery, considered highly complex, like other surgeries with a high postoperative morbidity and mortality rate, may be one of the specialties that most benefit from the implementation of these programs. This review presents the recommendations made by different specialties involved in the perioperative care of patients who require resection of a lung tumor. Meta-analyses, systematic reviews, randomized and non-randomized controlled studies, and retrospective studies conducted in patients undergoing this type of intervention have been taken into account in preparing the recommendations presented in this guide. The GRADE scale has been used to classify the recommendations, assessing on the one hand the level of evidence published on each specific aspect and, on the other hand, the strength of the recommendation with which the authors propose its application. The recommendations considered most important for this type of surgery are those that refer to pre-habilitation, minimization of surgical aggression, excellence in the management of perioperative pain and postoperative care aimed at providing rapid postoperative rehabilitation.
Collapse
Affiliation(s)
- I Garutti
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España; Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España.
| | - A Cabañero
- Servicio de Cirugía Torácica, Hospital Universitario Ramón y Cajal, Madrid, España
| | - R Vicente
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, España
| | - D Sánchez
- Servicio de Cirugía Torácica, Hospital Clínic, Barcelona, España
| | - M Granell
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, España
| | - C A Fraile
- Servicio de Cirugía Torácica, Hospital Universitari Arnau de Vilanova, Lleida, España
| | - M Real Navacerrada
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, España
| | - N Novoa
- Servicio de Cirugía Torácica, Complejo Asistencial Universitario de Salamanca (CAUS), Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, España
| | - G Sanchez-Pedrosa
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - M Congregado
- Servicio de Cirugía Torácica, Hospital Virgen de la Macarena, Sevilla, España
| | - A Gómez
- Unitat de Rehabilitació Cardiorespiratòria, Hospital Universitari Vall d'Hebron, Barcelona, España
| | - E Miñana
- Servicio de Anestesia y Reanimación, Hospital de La Ribera, Alzira, Valencia, España
| | - P Piñeiro
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - P Cruz
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - F de la Gala
- Servicio de Anestesia y Reanimación, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - F Quero
- Servicio de Cirugía Torácica, Hospital Universitario Virgen de las Nieves, Granada, España
| | - L J Huerta
- Servicio de Cirugía Torácica, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - M Rodríguez
- Servicio de Cirugía Torácica, Clínica Universidad de Navarra, Madrid, España
| | - E Jiménez
- Fisioterapia Respiratoria, Hospital Universitario de A Coruña, La Coruña, España
| | - L Puente-Maestu
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España
| | - S Aragon
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, España
| | - E Osorio-Salazar
- Servicio de Anestesia y Reanimación, Hospital Universitari Arnau de Vilanova, Lleida, España
| | - M Sitges
- Bloc Quirúrgic i Esterilització, Hospital del Mar, Parc de Salut Mar, Barcelona, España
| | | | - F T Rios
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, España
| | - J E Morales
- Servicio de Anestesia y Reanimación, Hospital General, Valencia, España
| | - R Callejas
- Servicio de Anestesia, Reanimación y Tratamiento del Dolor, Hospital Clínico Universitario, Valencia, España
| | - S Gonzalez-Bardancas
- Servicio de Anestesia y Reanimación, Complejo Hospitalario Universitario A Coruña, La Coruña, España
| | - S Botella
- Servicio de Anestesia y Reanimación, Hospital La Fe, Valencia, España
| | - M Cortés
- Servicio de Anestesia y Reanimación, Hospital Universitario 12 de Octubre, Madrid, España
| | - M J Yepes
- Servicio de Anestesia y Reanimación, Clínica Universidad de Navarra, Navarra, Pamplona, España
| | - R Iranzo
- Servicio de Anestesia y Reanimación, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España
| | - J Sayas
- Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, España
| |
Collapse
|
6
|
Gutierrez-Sainz L, Cruz P, Martinez-Recio S, Higuera O, Esteban-Rodriguez MI, Arias-Lotto F, Gonzalez RA, De Castro-Carpeño J. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression. Clin Transl Oncol 2021; 23:2030-2035. [PMID: 33837910 DOI: 10.1007/s12094-021-02605-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 03/22/2021] [Indexed: 01/09/2023]
Abstract
BACKGROUND Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management of patients with MPM and sought to determine whether pre-treatment levels of derived neutrophil-to-lymphocyte ratio (dNLR) as well as PD-L1 expression were reliable prognostic factors of survival. METHODS We conducted a single-institution retrospective study, including all patients with MPM treated at La Paz University Hospital between December 2009 and March 2018. Baseline disease, demographics, clinical data, treatment characteristics and complete blood cell counts were collected. We examined dNLR at baseline and data for PD-L1 expression were analyzed in tumor cells by immunohistochemistry. RESULTS We included 25 patients. The median overall survival (OS) was 15.7 months (95% CI 11.3-20.0). 5 patients had a dNLR greater than 3 (20%). Patients with a dNLR greater than 3 had shorter median OS (8.5 months), than patients with a dNLR less than 3 (17.0 months), with statistically significant differences (p = 0.038). Ten patients (40%) had positive PD-L1 expression (≥ 1%). Patients with positive PD-L1 expression had shorter median OS (8.5 months) than patients with negative PDL1 expression (15.7 months), but without statistically significant association (p = 0.319). CONCLUSION The survival data obtained in our sample are consistent with those previously reported. Pretreatment levels of dNLR greater than 3 and positive PD-L1 expression could be significant prognostic factors for poor survival in patients with MPM. Further and prospective studies are needed to explore this relationship and to derive definitive conclusions.
Collapse
Affiliation(s)
- L Gutierrez-Sainz
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain.
| | - P Cruz
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain
| | - S Martinez-Recio
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain
| | - O Higuera
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain
| | - M I Esteban-Rodriguez
- Pathology Department, Hospital Universitario La Paz, Madrid, Spain
- Translational Oncology Group, IdiPAZ, Madrid, Spain
| | - F Arias-Lotto
- Pathology Department, Hospital Universitario La Paz, Madrid, Spain
| | - R A Gonzalez
- De La Salle Medical and Health Sciences Institute, Dasmariñas, Philippines
| | - J De Castro-Carpeño
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, 28046, Madrid, Spain
- Translational Oncology Group, IdiPAZ, Madrid, Spain
- Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
7
|
Gutierrez-Sainz L, Martinez-Marin V, Viñal D, Martinez-Perez D, Pedregosa J, Garcia-Cuesta JA, Villamayor J, Zamora P, Pinto A, Redondo A, Castelo B, Cruz P, Higuera O, Custodio A, Gallego A, Sanchez-Cabrero D, de Castro-Carpeño J, Espinosa E, Feliu J. Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. Clin Transl Oncol 2020; 23:1245-1252. [PMID: 33231859 DOI: 10.1007/s12094-020-02515-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 10/18/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND Cancer and cancer therapies have been associated with an increased incidence of venous thromboembolic events (VTE). However, the incidence of VTE in patients on immunotherapy has not been well characterized. The aim of this study was to assess the incidence of VTE in cancer patients receiving immunotherapy and ascertain its prognostic utility. MATERIALS AND METHODS We conducted a single-institution retrospective study, including all cancer patients treated with anti-Programmed cell Death 1 (PD-1), anti-Programmed cell Death Ligand-1 (PD-L1), anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4), a combination of anti-PD-1/anti-PD-L1 and anti-CTLA4 or a combination including any of these drugs with chemotherapy, antiangiogenic agents or both between June 2013 and April 2019 at La Paz University Hospital, Madrid (Spain). RESULTS We selected 229 patients. VTE occurred in 16 of 229 patients (7%). VTE occurred more frequently in patients with lung cancer followed by melanoma. Female sex and melanoma were independently associated with an increased risk of VTE. 12 of 16 VTE (75%) were symptomatic. Progressive disease to immunotherapy [HR 31.60 (95% CI 11.44-87.22), p = 0.00], lung cancer [HR 2.55 (95% CI 1.34-4.86), p = 0.00] and melanoma [HR 2.42 (1.20-4.86), p = 0.01] were independently associated with shorter OS. VTE occurrence was not independently associated with shorter OS [HR 1.33 (95% CI 0.63-2.80), p = 0.44]. CONCLUSIONS The incidence of VTE in cancer patients receiving immunotherapy in our study appeared to be similar to the incidence previously reported in other series of cancer patients treated with systemic therapies. VTE occurrence did not correlate with the prognosis. Further and prospective studies are needed to derive definitive conclusions.
Collapse
Affiliation(s)
- L Gutierrez-Sainz
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.
| | - V Martinez-Marin
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain.,Cancer & Thrombosis Section, Spanish Society of Medical Oncology (SEOM), Madrid, Spain
| | - D Viñal
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - D Martinez-Perez
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - J Pedregosa
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - J A Garcia-Cuesta
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - J Villamayor
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - P Zamora
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain.,Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
| | - A Pinto
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain
| | - A Redondo
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain.,Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.,Cátedra UAM-AMGEN, Madrid, Spain
| | - B Castelo
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain.,Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.,Cátedra UAM-AMGEN, Madrid, Spain
| | - P Cruz
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - O Higuera
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - A Custodio
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain
| | - A Gallego
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - D Sanchez-Cabrero
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain
| | - J de Castro-Carpeño
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain.,Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC, Madrid, Spain.,Cátedra UAM-AMGEN, Madrid, Spain
| | - E Espinosa
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain.,Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC, Madrid, Spain.,Cátedra UAM-AMGEN, Madrid, Spain
| | - J Feliu
- Medical Oncology Department, Hospital Universitario La Paz, IdiPAZ, Paseo de la Castellana 261, Madrid, 28046, Spain.,Translational Oncology Group, IdiPAZ, Madrid, Spain.,Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC, Madrid, Spain.,Cátedra UAM-AMGEN, Madrid, Spain
| |
Collapse
|
8
|
Chung J, Ramani V, Cruz P, Savory S, Ariizumi K. 701 Dysplastic nevi (DN) patients have high DC-HIL-expressing myeloid-derived suppressor cells (MDSC) that may confer increased risk for melanoma. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Fernández I, Fernández M, Marín P, Martínez V, Molero F, Borrás A, Gómez M, Laínez E, Cruz P, Molo C, Recio M, Argudo C, Rodríguez C. P-08-9 Female Genital Self Image Scale: Adaptation and Validation INTO Spanish. J Sex Med 2020. [DOI: 10.1016/j.jsxm.2020.04.371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
10
|
Cruz P, Sosoniuk-Roche E, Maldonado I, Torres CG, Ferreira A. Trypanosoma cruzi calreticulin: In vitro modulation of key immunogenic markers of both canine tumors and relevant immune competent cells. Immunobiology 2019; 225:151892. [PMID: 31837774 DOI: 10.1016/j.imbio.2019.12.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 12/01/2019] [Accepted: 12/01/2019] [Indexed: 10/25/2022]
Abstract
Recombinant calreticulin from Trypanosoma cruzi (rTcCalr), the parasite responsible for Chagas' disease, binds to Canine Transmissible Venereal Tumor (CTVT) cells from primary cultures and to a canine mammary carcinoma cell line. A Complement-binding assay indicated that interaction of the first component C1q with these tumor cells operated independently of the rTcCalr-presence. This apparent independence could be explained by the important structural similarities that exist among rTcCarl, endogenous normal canine and/or mutated calreticulins present in several types of cancer. In phagocytosis assays, tumor cells treated with rTcCalr were readily engulfed by macrophages and, co-cultured with DCs, accelerated their maturation. In addition, DCs maturation, induced by tumor cells co-cultured with rTcCalr, activated T cells more efficiently than DCs, treated or not with LPS. In an apparent paradox, a decrease in MHC Class I expression was observed when these tumor cells were co-cultivated with rTcCalr. This decrease may be related to a down regulation signaling promoting the rescue of MHC I. Possibly, these in vitro assays may be valid correlates of in vivo sceneries. Based on these results, we propose that rTcCalr improves in vitro the immunogenicity of two widely different tumor cell lines, thus suggesting that the interesting properties of rTcCalr to boost immune responses warrant future studies.
Collapse
Affiliation(s)
- P Cruz
- Laboratory of Immunology of Microbial Aggression, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, 8380453, Chile; Laboratory of Biomedicine and Regenerative Medicine, Department of Clinical Sciences, Faculty of Veterinary and Animal Sciences, University of Chile, Santiago, 8820808, Chile
| | - E Sosoniuk-Roche
- Laboratory of Immunology of Microbial Aggression, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, 8380453, Chile
| | - I Maldonado
- Laboratory of Immunology of Microbial Aggression, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, 8380453, Chile
| | - C G Torres
- Laboratory of Biomedicine and Regenerative Medicine, Department of Clinical Sciences, Faculty of Veterinary and Animal Sciences, University of Chile, Santiago, 8820808, Chile.
| | - A Ferreira
- Laboratory of Immunology of Microbial Aggression, Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, 8380453, Chile.
| |
Collapse
|
11
|
Rubio XM, Garcia MEO, Moyano MS, Aguado C, Núñez J, Gomez MD, Peña AMS, Ariza IN, Gonzalez SC, Cabellos RA, Gutiérrez LC, Mendez CP, Cervera R, Blanco AC, Castro RL, Torres JMS, Martin AL, Ordonez AV, Fernández EP, Cruz P. Predictive model for survival in advanced non-small cell lung cancer (NSCLC) treated with frontline pembrolizumab. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.087] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Cruz P, Sainz LG, Aguado C, Antoñanzas M, Mielgo X, Cabezón L, Chara L, Gomez-Barreda I, Moreno EM, Alfranca YL, Velastegui A, Sotelo M, Rueda AG, Olmedo M, Recio SM, De Castro Carpeno J. P2.01-55 Immunotherapy First or After Nintedanib?: A Spanish Experience. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Rubio XM, Aguado C, Sereno M, Chara L, Cabezón L, Velastegui A, López A, Castro RL, Sotelo M, Rubio J, Núñez J, Fernández EP, Olier C, De Castro Carpeno J, Antoñanzas M, Falagan S, Gomez-Barreda I, Custodio S, Cruz P. P1.04-16 Early Antibiotic Use Affects the Efficacy of First Line Immunotherapy in Lung Cancer Patients but Route of Administration Seems to be Decisive. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.919] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Cabrero DS, Cruz P, Perez P, Martinez S, Higuera O, Pertejo A, Esteban I, Gutierrez L, Villamayor J, Viñal D, Torres J, Ramón J, De Castro Carpeno J. EP1.12-20 Retrospective Study About the Impact of Metastatic Site in Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Sainz LG, Cruz P, Recio SM, Esteban I, Lotto FA, Viñal D, Villamayor J, Cabrero DS, Higuera O, De Castro Carpeno J. EP1.06-11 Advanced Malignant Pleural Mesothelioma: A Single Institution Experience. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
16
|
Cabrero DS, Cruz P, Miranda J, Higuera O, Pertejo A, Ramón J, Torres J, Gutierrez L, Villamayor J, Viñal D, Esteban I, De Castro Carpeno J. EP1.14-31 Retrospective Study About EGFR Mutations in Lung Cancer: Our Experience in a Spanish Hospital. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Cabrero DS, Cruz P, Martinez S, Perez P, Higuera O, Pertejo A, Esteban I, Gutierrez L, Villamayor J, Viñal D, Torres J, Ramón J, De Castro Carpeno J. EP1.12-29 Retrospective Study About Small Cell Lung Cancer: Our Experience in a Spanish Hospital. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
18
|
Cabrero DS, Cruz P, Martinez S, Perez P, Pertejo A, Higuera O, Gutierrez L, Villamayor J, Viñal D, Esteban I, Torres J, Ramón J, De Castro Carpeno J. EP1.12-26 Retrospective Study About the Impact of Brain Metastases and Cranial Irradiation in Small Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Gutiérrez Sainz L, Martínez-Marin V, Viñal Lozano D, Martínez Pérez D, Pedregosa Barbas J, García Cuesta J, Villamayor Sánchez J, Zamora P, Pinto Marin A, Castelo B, Redondo A, Gallego Martínez A, Cruz P, Higuera Gomez O, Custodio A, Sánchez Cabrero D, De Castro Carpeno J, Espinosa E, Feliu Batlle J. Incidence of vascular thromboembolism events in cancer patients receiving immunotherapy: A single institution experience. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz265.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Cruz P, Recio SM, Mielgo X, Peña VS, Chara L, Ariza IN, Moreno EM, Alfranca YL, Velastegui A, Sainz LG, De Castro Carpeno J. EP1.06-09 Mesothelial Tumors Registry in Spain: A Retrospective Multicenter Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
21
|
Cruz P, Sainz LG, Antoñanzas M, Aguado C, Mielgo X, Cabezón L, Chara L, Moreno EM, Alfranca YL, Velastegui A, Sotelo M, Rueda AG, Olmedo M, Recio SM, De Castro Carpeno J. P2.01-81 Predictive Factors of Survival in Patients Treated with Nintedanib: A Multicenter Retrospective Spanish Study. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
22
|
Mielgo Rubio X, Gomez Rueda A, Antoñanzas M, Falagan S, Núñez J, Sánchez Peña A, Gómez-Barreda I, Martinez Moreno E, Cerezo Gonzalez S, Cabezón Gutiérrez L, Sanchez Torres J, Jimenez Munarriz B, Cervera R, Pangua Mendez C, Calles Blanco A, Lopez Martin A, López Castro R, Sotelo Lezama M, Pérez Fernández E, Cruz P. Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.031] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Sainz LG, Cruz P, Villamayor J, Recio SM, Esteban I, Lotto FA, Viñal D, Cabrero DS, Higuera O, De Castro Carpeno J. EP1.18-28 Neoadjuvant Therapy Among Patients Undergoing Resection for Non-Small-Cell Lung Cancer: A Single Institution Experience. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.2472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Cruz P, Reyes F, Torres CG. Simvastatin modulates β-catenin/MDR1 expression on spheres derived from CF41.Mg canine mammary carcinoma cells. Pol J Vet Sci 2019; 21:95-99. [PMID: 29624022 DOI: 10.24425/119026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The presence of cancer stem-like cells (CSC) within canine mammary tumors, may explain partly local recurrence and spreading, since their ability to resist conventional antitumor treatments as chemo and radiotherapy. It has been recently described that simvastatin - a drug that inhibits synthesis of cholesterol - attenuates the proliferation of canine mammary CSC derived from CF41.Mg canine mammary carcinoma cells, promoting their chemosensitizing and apoptosis. The canonical Wnt/β-catenin pathway is usually activated at CSC and up-regulates multidrug resistance protein 1 (MDR1), triggering chemoresistance. In the present study, we analyze the effect of simvastatin on β-catenin/MDR1 expression in spheres obtained from the CF41.Mg cell line as a model of CSC. Simvastatin increased phosphorylation of β-catenin without affecting its total expression. Moreover, MDR1 expression was decreased by simvastatin. These results suggest that simvastatin would facilitate the degradation of β-catenin, decreasing MDR1 expression and contributing to the chemosensitizing effects of the statin on canine mammary CSC.
Collapse
Affiliation(s)
- P Cruz
- Laboratory of Biomedicine and Regenerative Medicine, Department of Clinical Sciences, Faculty of Veterinary and Animal Sciences, University of Chile, Santa Rosa Avenue 11735, La Pintana, 8820808 Chile.,Ph.D program in Forestry, Agricultural and Veterinary Sciences, Faculty of Veterinary and Animal Sciences, University of Chile, Santa Rosa Avenue 11735, La Pintana, 8820808 Chile
| | - F Reyes
- Laboratory of Biomedicine and Regenerative Medicine, Department of Clinical Sciences, Faculty of Veterinary and Animal Sciences, University of Chile, Santa Rosa Avenue 11735, La Pintana, 8820808 Chile
| | - C G Torres
- Laboratory of Biomedicine and Regenerative Medicine, Department of Clinical Sciences, Faculty of Veterinary and Animal Sciences, University of Chile, Santa Rosa Avenue 11735, La Pintana, 8820808 Chile
| |
Collapse
|
25
|
Kin N, Leidinger-Kaufmann P, Cruz P, Mei R, Saikia J, Steimer M. Performance comparison of the fast track diagnostics multiplex real-time PCR assays on two different automated molecular platforms. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.1198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Ramani V, Chung J, Kobayashi M, Cruz P, Ariizumi K. 063 The DC-HIL/syndecan-4 (SD4) pathway regulates trafficking of effector T-lymphocytes from blood to skin. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
27
|
Chung J, Ramani V, Kobayashi M, Cruz P, Ariizumi K. 824 DC-HIL expression determines response of metastatic B16 melanoma and LL2 lung carcinoma to anti-PDL1 treatment. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
Cabrero D, Cruz P, de Castro J, Higuera O, Pertejo A, Esteban I, Gutierrez L, Villamayor J, Ostios L, Viñal D, Miranda J. Retrospective study about lung carcinoid: Our experience in a Spanish hospital. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz065.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Matos P, Figueirinha A, Paranhos A, Nunes F, Cruz P, Geraldes CFGC, Cruz MT, Batista MT. Bioactivity of Acanthus mollis - Contribution of benzoxazinoids and phenylpropanoids. J Ethnopharmacol 2018; 227:198-205. [PMID: 30201231 DOI: 10.1016/j.jep.2018.09.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 09/03/2018] [Accepted: 09/06/2018] [Indexed: 06/08/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Acanthus mollis is a plant native to the Mediterranean region, traditionally used as diuretic, anti-inflammatory and soothing of the mucous membranes of the digestive and urinary tract and externally as healing of wounds and burns, also demonstrating analgesic and anti-inflammatory activities. However, studies focused on its phytochemical composition as well as scientific proof of Acanthus mollis efficacy are scarce. AIM OF THE STUDY The proposed work aims to perform a phytochemical characterization and evaluation of the therapeutic potential of Acanthus mollis, based on biological properties that support its traditional uses. MATERIAL AND METHODS In this study, an 96% ethanol extract from Acanthus mollis leaves was obtained and its phytochemical composition evaluated using High Performance Liquid Chromatography with Photodiode Array Detector coupled to Electrospray Ionization Mass Spectrometry (HPLC-PDA-ESI/MSn). The chemical structure of the compound isolated was elucidated using 1H and 13C Nuclear Magnetic Resonance (NMR), 1H-correlation spectroscopy (1H-COSY), heteronuclear single quantum correlation (HSQC) and heteronuclear multiple-bond correlation (HMBC). The quantification of the constituents was performed using two external standards (2,4-dihydroxy-1,4-benzoxazin-3-one and verbascoside). The antioxidant activity was determined by the 2,2-diphenyl-1-pycrylhydrazyl (DPPH) assay. Anti-inflammatory activity was determined measuring the inhibition of nitric oxide production by RAW 264.7 macrophages stimulated with the TLR4 agonist lipopolysaccharide (LPS) and through lipoxygenase (LOX) inhibition assay. The cytotoxicity was screened on two lines (RAW 264.7 and HaCaT) using the resazurin assay. RESULTS Compounds such as verbascoside and its derivatives, as well as benzoxazinoids were found as the main constituents. A percentage of 5.58% was verified for the 2,4-dihydroxy-1,4-benzoxazin-3-one (DIBOA) derivatives. DIBOA was the main compound of the extract. Significant concentrations were also found for phenylpropanoids, which constitute about 4.39% of the total compounds identified. This extract showed antioxidant capacity against DPPH (IC50 = 40.00 ± 1.59 μg/mL) and superoxide anion (IC50 = 29.42 ± 1.99 μg/mL). It also evidenced anti-inflammatory potential in RAW 264.7 macrophages, presenting capacity for nitric oxide reduction (IC50 = 28.01 μg/mL). Moreover, in vitro studies have shown that this extract was able to inhibit the lipoxygenase, with an IC50 of 104.39 ± 4.95 µg/mL. Importantly, all effective concentrations were devoid of cytotoxicity in keratinocytes, thus highlighting the safety of the extract for the treatment of skin inflammatory related diseases. Concerning macrophages it was also possible to disclose concentrations showing anti-inflammatory activity and without cytotoxicity (up to 30 µg/mL). The benzoxazinoid DIBOA demonstrated a considerable anti-inflammatory activity suggesting its important contribution to this activity. CONCLUSIONS These results corroborate the anti-inflammatory properties traditionally attributed to this plant. Among the compounds identified in this study, benzoxazinoids exhibited a significant anti-inflammatory activity that was never previously described. Ethanol seems to be a good option for the extraction of these bioactive compounds, since relevant antioxidant/anti-radical and anti-inflammatory activities were found for this extract.
Collapse
Affiliation(s)
- P Matos
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; LAQV, REQUIMTE, Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
| | - A Figueirinha
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; LAQV, REQUIMTE, Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
| | - A Paranhos
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Center for Pharmaceutical Studies, Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
| | - F Nunes
- Center for Neurosciences and Cell Biology, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
| | - P Cruz
- Coimbra Chemistry Centre (CQC), Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal
| | - C F G C Geraldes
- Coimbra Chemistry Centre (CQC), Department of Chemistry, University of Coimbra, Rua Larga, 3004-535 Coimbra, Portugal; Department of Life Sciences, Faculty of Science and Technology, University of Coimbra, Calçada Martim de Freitas, 3000-393 Coimbra, Portugal
| | - M T Cruz
- Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; Center for Neurosciences and Cell Biology, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
| | - M T Batista
- Center for Pharmaceutical Studies, Faculty of Pharmacy, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal; CIEPQPF, Department of Chemical Engineering, Faculty of Science and Technology, University of Coimbra, 3030-790 Coimbra, Portugal
| |
Collapse
|
30
|
Woodard DR, Buttner M, Cruz P, Roeder J. Microbial contamination of privacy curtains in the emergency department of a metropolitan hospital. J Hosp Infect 2018; 100:e153-e154. [PMID: 29958915 DOI: 10.1016/j.jhin.2018.06.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 06/21/2018] [Indexed: 10/28/2022]
Affiliation(s)
- D R Woodard
- Department of Environmental and Occupational Health, School of Community Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.
| | - M Buttner
- Department of Environmental and Occupational Health, School of Community Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA
| | - P Cruz
- Department of Environmental and Occupational Health, School of Community Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA
| | - J Roeder
- Spring Valley Hospital Medical Centre, Las Vegas, NV, USA
| |
Collapse
|
31
|
Rego Silva J, Macau R, Oliveira Coelho H, Camelo F, Cruz P, Mateus A, Oliveira A, Oliveira C, Ramos A. Late-Onset Post-transplantation Central Nervous System Lymphoproliferative Disorder: Case Report. Transplant Proc 2018; 50:857-860. [DOI: 10.1016/j.transproceed.2018.02.018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Rego Silva J, Macau RA, Mateus A, Cruz P, Aleixo MJ, Brito M, Alcobia A, Oliveira C, Ramos A. Successful Treatment of Strongyloides stercoralis Hyperinfection in a Kidney Transplant Recipient: Case Report. Transplant Proc 2018; 50:861-866. [PMID: 29661454 DOI: 10.1016/j.transproceed.2018.02.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Strongyloides stercoralis (SS) can cause hyperinfection and disseminated infection in immunosuppressed individuals, with risk of mortality. We report the case of a cadaveric kidney transplant recipient who developed gastrointestinal symptoms and eosinophilia, approximately 3 months after transplantation. Stool examination and esophagogastroduodenoscopy with biopsies were positive for SS larvae. The patient was started on oral ivermectin and immunosuppression was reduced, but still the clinical picture got worse with metabolic ileus and respiratory symptoms, with the need for administration of subcutaneous ivermectin and combined therapy with albendazol. The patient survived and graft function was preserved. The patient was unlikely to be the source of infection. We also present a review of cases of SS infection in kidney transplant recipients.
Collapse
Affiliation(s)
- J Rego Silva
- Nephrology Department, Hospital Garcia de Orta, Almada, Portugal.
| | - R A Macau
- Nephrology Department, Hospital Garcia de Orta, Almada, Portugal
| | - A Mateus
- Nephrology Department, Hospital Garcia de Orta, Almada, Portugal
| | - P Cruz
- Nephrology Department, Hospital Garcia de Orta, Almada, Portugal
| | - M J Aleixo
- Infectious Diseases Department, Hospital Garcia de Orta, Almada, Portugal
| | - M Brito
- Pharmacy, Hospital Garcia de Orta, Almada, Portugal
| | - A Alcobia
- Pharmacy, Hospital Garcia de Orta, Almada, Portugal
| | - C Oliveira
- Nephrology Department, Hospital Garcia de Orta, Almada, Portugal
| | - A Ramos
- Nephrology Department, Hospital Garcia de Orta, Almada, Portugal
| |
Collapse
|
33
|
de la Gala F, Piñeiro P, Reyes A, Vara E, Olmedilla L, Cruz P, Garutti I. Postoperative pulmonary complications, pulmonary and systemic inflammatory responses after lung resection surgery with prolonged one-lung ventilation. Randomized controlled trial comparing intravenous and inhalational anaesthesia. Br J Anaesth 2017; 119:655-663. [DOI: 10.1093/bja/aex230] [Citation(s) in RCA: 70] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/22/2017] [Indexed: 11/14/2022] Open
|
34
|
Tomas L, Vecchio N, Orosco A, Vergara J, Mondragon I, Cruz P, Rivera S, Caro M, Albina G, Giniger A, Scazzuso F. P2654Paroxysmal atrial fibrillation ablation: the blanking period as a new recurrence predictor. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Tomas L, Tomas L, Orosco A, Vergara JM, Mondragon F, Cruz P, Caro M, Reinoso M, Rivera S, Albina G, Giniger A, Scazzuso F. P880Paroxysmal atrial fibrillation ablation: the blanking period as a new recurrence predictor. Europace 2017. [DOI: 10.1093/ehjci/eux151.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Cipriano M, Correia JC, Camões SP, Oliveira NG, Cruz P, Cruz H, Castro M, Ruas JL, Santos JM, Miranda JP. The role of epigenetic modifiers in extended cultures of functional hepatocyte-like cells derived from human neonatal mesenchymal stem cells. Arch Toxicol 2016; 91:2469-2489. [PMID: 27909741 DOI: 10.1007/s00204-016-1901-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Accepted: 11/24/2016] [Indexed: 01/06/2023]
Abstract
The development of predictive in vitro stem cell-derived hepatic models for toxicological drug screening is an increasingly important topic. Herein, umbilical cord tissue-derived mesenchymal stem cells (hnMSCs) underwent hepatic differentiation using an optimized three-step core protocol of 24 days that mimicked liver embryogenesis with further exposure to epigenetic markers, namely the histone deacetylase inhibitor trichostatin A (TSA), the cytidine analogue 5-azacytidine (5-AZA) and dimethyl sulfoxide (DMSO). FGF-2 and FGF-4 were also tested to improve endoderm commitment and foregut induction during Step 1 of the differentiation protocol, being HHEX expression increased with FGF-2 (4 ng/mL). DMSO (1%, v/v) when added at day 10 enhanced cell morphology, glycogen storage ability, enzymatic activity and induction capacity. Moreover, the stability of the hepatic phenotype under the optimized differentiation conditions was examined up to day 34. Our findings showed that hepatocyte-like cells (HLCs) acquired the ability to metabolize glucose, produce albumin and detoxify ammonia. Global transcriptional analysis of the HLCs showed a partial hepatic differentiation degree. Global analysis of gene expression in the different cells revealed shared expression of gene groups between HLCs and human primary hepatocytes (hpHeps) that were not observed between HepG2 and hpHeps. In addition, bioinformatics analysis of gene expression data placed HLCs between the HepG2 cell line and hpHeps and distant from hnMSCs. The enhanced hepatic differentiation observed was supported by the presence of the hepatic drug transporters OATP-C and MRP-2 and gene expression of the hepatic markers CK18, TAT, AFP, ALB, HNF4A and CEBPA; and by their ability to display stable UGT-, EROD-, ECOD-, CYP1A1-, CYP2C9- and CYP3A4-dependent activities at levels either comparable with or even higher than those observed in primary hepatocytes and HepG2 cells. Overall, an improvement of the hepatocyte-like phenotype was achieved for an extended culture time suggesting a role of the epigenetic modifiers in hepatic differentiation and maturation and presenting hnMSC-HLCs as an advantageous alternative for drug discovery and in vitro toxicology testing.
Collapse
Affiliation(s)
- M Cipriano
- Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal
| | - J C Correia
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - S P Camões
- Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal
| | - N G Oliveira
- Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal
| | - P Cruz
- ECBio S.A., Amadora, Portugal
| | - H Cruz
- ECBio S.A., Amadora, Portugal
| | - M Castro
- Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal
| | - J L Ruas
- Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | | | - J P Miranda
- Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003, Lisbon, Portugal.
| |
Collapse
|
37
|
Joseph E, Rindani P, Cruz P, Tribhuvan V. ISQUA16-2352STREAMING QUIET TIME TO ENSURE ADEQUATE REST FOR PATIENTS. Int J Qual Health Care 2016. [DOI: 10.1093/intqhc/mzw104.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Querido S, Machado D, Silva C, Nolasco F, Nunes A, Sampaio S, Cruz P, Oliveira C, Weigert A. Renal Transplantation in HIV-Infected Patients: The First Portuguese Review. Transplant Proc 2016; 47:946-9. [PMID: 26036491 DOI: 10.1016/j.transproceed.2015.03.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION With the introduction of combination antiretroviral therapy (cART), prognosis of human immunodeficiency virus (HIV) infection has been improved and kidney transplantation (KT) in HIV-positive patients became possible. METHODS We reviewed the demographic, clinical, laboratory, and therapeutic data of all the HIV-infected patients who underwent KT between 2009 (first KT in Portugal in a HIV-infected patient) and May 2014. Case accrual was through all Portuguese KT centers where a KT in an HIV-infected patient was performed. Patients were transplanted following the American and Spanish guideline recommendations that included maintenance on cART, undetectable plasma HIV RNA copies, and absolute CD4 counts of ≥ 200 cells/μL in the last 6 months. RESULTS Fourteen KT were performed on men and 3 on women. The mean age of patients at the time of transplantation was 49.9 ± 11.7 years. HIV status was known for 12 ± 5 years. Eight patients had AIDS in the past and all patients received grafts from deceased donors. Twelve patients (64.7%) underwent induction therapy with basiliximab and 2 patients experienced early graft loss. In 2 patients, humoral rejection was diagnosed and in 3 patients, cellular rejection. Two patients died and an additional patient had early graft loss. CONCLUSION KT is a possible, but challenging, renal replacement therapy in selected HIV-positive patients. Even in those with AIDS criteria in the past, when the disease is controlled, and after the reconstitution of the immune system with cART, KT can be performed. Nevertheless, the risk-benefit ratio for each patient needs to be taken in consideration.
Collapse
Affiliation(s)
- S Querido
- Nephrology, Centro Hospitalar do Médio Tejo, Torres Novas, Portugal.
| | - D Machado
- Nephrology, Centro Hospitalar de Lisboa Ocidental, Hospital de Santa Cruz, Carnaxide, Portugal
| | - C Silva
- Nephrology, Centro Hospitalar de Lisboa Central, Hospital Curry Cabral, Lisboa, Portugal
| | - F Nolasco
- Nephrology, Centro Hospitalar de Lisboa Central, Hospital Curry Cabral, Lisboa, Portugal
| | - A Nunes
- Nephrology, Hospital de São João, Porto, Portugal
| | - S Sampaio
- Nephrology, Hospital de São João, Porto, Portugal
| | - P Cruz
- Nephrology, Hospital Garcia de Orta, Almada, Portugal
| | - C Oliveira
- Nephrology, Hospital Garcia de Orta, Almada, Portugal
| | - A Weigert
- Nephrology, Centro Hospitalar de Lisboa Ocidental, Hospital de Santa Cruz, Carnaxide, Portugal
| |
Collapse
|
39
|
Cruz P, Rocha F, Ferreira A. Effect of operating conditions on batch and continuous paracetamol crystallization in an oscillatory flow mesoreactor. CrystEngComm 2016. [DOI: 10.1039/c6ce01648k] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
40
|
|
41
|
Santos T, Rocha Z, Vasconcelos V, Lara E, Palmieri H, Cruz P, Gouvea V, Siqueira J, Oliveira A. Evaluation of natural radionuclides in Brazilian underground mines. Radiat Phys Chem Oxf Engl 1993 2015. [DOI: 10.1016/j.radphyschem.2015.04.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
42
|
Camões S, Santos J, Gaspar M, Simões S, Bárcia R, Cruz H, Cruz P, Castro M, Miranda J. Human neonatal mesenchymal stem cell spheroids-conditioned medium accelerates skin regeneration. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.1075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
43
|
Cipriano M, Camões S, Proença S, Pinheiro P, Barcia R, Cruz P, Oliveira N, Castro M, Miranda J. Role of epigenetic modifiers on human neonatal mesenchymal stem cells differentiation into hepatocyte-like cells. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Cruz P, Alarcón L, Del Castillo T, Cabrerizo P, Díaz S. [Effectiveness of the GlideScope video laryngoscope in a case of unexpected difficult airway due to lingual tonsil hypertrophy]. ACTA ACUST UNITED AC 2014; 62:289-92. [PMID: 25487764 DOI: 10.1016/j.redar.2014.09.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Revised: 09/15/2014] [Accepted: 09/25/2014] [Indexed: 12/17/2022]
Abstract
Lingual tonsil hypertrophy can cause varying degrees of airway obstruction and is considered a risk factor for difficult mask ventilation and tracheal intubation. We report a case of unexpected difficult airway in a patient with unknown lingual tonsil hypertrophy that was solved with the use of the GlideScope video laryngoscope.
Collapse
Affiliation(s)
- P Cruz
- Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Hospital General Universitario Gregorio Marañón, Madrid, España.
| | - L Alarcón
- Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - T Del Castillo
- Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - P Cabrerizo
- Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Hospital General Universitario Gregorio Marañón, Madrid, España
| | - S Díaz
- Servicio de Anestesiología, Reanimación y Tratamiento del Dolor, Hospital General Universitario Gregorio Marañón, Madrid, España
| |
Collapse
|
45
|
Pinto A, Garrido M, Cruz P, Lopez D, Zambrana F, Aguayo C, Feliu J, Espinosa E. Early-Onset Hypothyroidism and Survival in Patients with Advanced Renal Cell Carcinoma Treated with First-Line Sunitinib: Updated Overall Survival Data. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Mendiola M, Redondo A, Barriuso J, Heredia V, Cruz P, Castelo Fernández B, De Santiago J, Diaz E, Miguel M, Yebenes L, Hardisson D. Association Between Angiogenesis-Related Genes and the Response to Multimodal Therapy in High Grade Serous Advanced Ovarian Carcinoma (Aoc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu338.32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Santos TO, Rocha Z, Cruz P, Gouvea VA, Siqueira JB, Oliveira AH. Radon dose assessment in underground mines in Brazil. Radiat Prot Dosimetry 2014; 160:120-123. [PMID: 24723186 DOI: 10.1093/rpd/ncu066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Underground miners are internally exposed to radon, thoron and their short-lived decay products during the mineral processing. There is also an external exposure due to the gamma emitters present in the rock and dust of the mine. However, the short-lived radon decay products are recognised as the main radiation health risk. When inhaled, they are deposited in the respiratory system and may cause lung cancer. To address this concern, concentration measurements of radon and its progeny were performed, the equilibrium factor was determined and the effective dose received was estimated in six Brazilian underground mines. The radon concentration was measured by using E-PERM, AlphaGUARD and CR-39 detectors. The radon progeny was determined by using DOSEman. The annual effective dose for the miners was estimated according to United Nations Scientific Committee on the Effects of Atomic Radiation methodologies. The mean value of the equilibrium factor was 0.4. The workers' estimated effective dose ranged from 1 to 21 mSv a(-1) (mean 9 mSv a(-1)).
Collapse
Affiliation(s)
- T O Santos
- Nuclear Engineering Department, Federal University of Minas Gerais, Av. Antônio Carlos, Belo Horizonte 6621, Brazil Anatomy and Image Department, Federal University of Minas Gerais, Av. Professor Alfredo Balena, Belo Horizonte 190, Brazil Environment Service, Development Center of the Nuclear Technology, Av. Antônio Carlos, Belo Horizonte 6621, Brazil
| | - Z Rocha
- Environment Service, Development Center of the Nuclear Technology, Av. Antônio Carlos, Belo Horizonte 6621, Brazil
| | - P Cruz
- Coordination of Raw Materials Control and Nuclear Minerals, National Nuclear Energy Commission, Rua Gal Severiano, Rio de Janeiro 90, Brazil
| | - V A Gouvea
- Coordination of Raw Materials Control and Nuclear Minerals, National Nuclear Energy Commission, Rua Gal Severiano, Rio de Janeiro 90, Brazil
| | - J B Siqueira
- Coordination of Raw Materials Control and Nuclear Minerals, National Nuclear Energy Commission, Rua Gal Severiano, Rio de Janeiro 90, Brazil
| | - A H Oliveira
- Nuclear Engineering Department, Federal University of Minas Gerais, Av. Antônio Carlos, Belo Horizonte 6621, Brazil
| |
Collapse
|
48
|
Gärtner A, Pereira T, Armada-da-Silva P, Amado S, Veloso A, Amorim I, Ribeiro J, Santos J, Bárcia R, Cruz P, Cruz H, Luís A, Santos J, Geuna S, Maurício A. Effects of umbilical cord tissue mesenchymal stem cells (UCX®) on rat sciatic nerve regeneration after neurotmesis injuries. J Stem Cells Regen Med 2014. [PMID: 25075157 PMCID: PMC4112274 DOI: 10.46582/jsrm.1001004] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Peripheral nerves have the intrinsic capacity of self-regeneration after traumatic injury but the extent of the regeneration is often very poor. Increasing evidence demonstrates that mesenchymal stem/stromal cells (MSCs) may play an important role in tissue regeneration through the secretion of soluble trophic factors that enhance and assist in repair by paracrine activation of surrounding cells. In the present study, the therapeutic value of a population of umbilical cord tissue-derived MSCs, obtained by a proprietary method (UCX®), was evaluated on end-to-end rat sciatic nerve repair. Furthermore, in order to promote both, end-to-end nerve fiber contacts and MSC cell-cell interaction, as well as reduce the flush away effect of the cells after administration, a commercially available haemostatic sealant, Floseal®, was used as vehicle. Both, functional and morphologic recoveries were evaluated along the healing period using extensor postural thrust (EPT), withdrawal reflex latency (WRL), ankle kinematics analysis, and either histological analysis or stereology, in the hyper-acute, acute and chronic phases of healing. The histological analysis of the hyper-acute and acute phase studies revealed that in the group treated with UCX® alone the Wallerian degeneration was improved for the subsequent process of regeneration, the fiber organization was higher, and the extent of fibrosis was lower. The chronic phase experimental groups revealed that treatment with UCX® induced an increased number of regenerated fibers and thickening of the myelin sheet. Kinematics analysis showed that the ankle joint angle determined for untreated animals was significantly different from any of the treated groups at the instant of initial contact (IC). At opposite toe off (OT) and heel rise (HR), differences were found between untreated animals and the groups treated with either uCx® alone or UCX® administered with Floseal®. Overall, the UCX® application presented positive effects in functional and morphologic recovery, in both the acute and chronic phases of the regeneration process. Kinematics analysis has revealed positive synergistic effects brought by Floseal® as vehicle for MSCs.
Collapse
Affiliation(s)
- A Gärtner
- Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal. ; Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA) , Rua D. Manuel II, Apartado 55142, 4051-401, Porto, Portugal. ; These authors contributed equally for the results present in this research work
| | - T Pereira
- Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal. ; Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA) , Rua D. Manuel II, Apartado 55142, 4051-401, Porto, Portugal. ; These authors contributed equally for the results present in this research work
| | - Pas Armada-da-Silva
- Faculdade de Motricidade Humana (FMH), Universidade de Lisboa (UL) , Estrada da Costa, 1499-002, Cruz Quebrada - Dafundo, Portugal. ; CIPER-FMH: Centro Interdisciplinar de Estudo de Performance Humana, Faculdade de Motricidade Humana (FMH) , Universidade de Lisboa (UL), Estrada da Costa, 1499-002, Cruz Quebrada - Dafundo, Portugal
| | - S Amado
- CIPER-FMH: Centro Interdisciplinar de Estudo de Performance Humana, Faculdade de Motricidade Humana (FMH) , Universidade de Lisboa (UL), Estrada da Costa, 1499-002, Cruz Quebrada - Dafundo, Portugal. ; UIS-IPL: Unidade de Investigação em Saúde da Escola Superior de Saúde de Leiria , Instituto Politécnico de Leiria, Portugal
| | - Ap Veloso
- Faculdade de Motricidade Humana (FMH), Universidade de Lisboa (UL) , Estrada da Costa, 1499-002, Cruz Quebrada - Dafundo, Portugal. ; CIPER-FMH: Centro Interdisciplinar de Estudo de Performance Humana, Faculdade de Motricidade Humana (FMH) , Universidade de Lisboa (UL), Estrada da Costa, 1499-002, Cruz Quebrada - Dafundo, Portugal
| | - I Amorim
- Departamento de Patologia e de Imunologia Molecular, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal. ; Instituto Português de Patologia e Imunologia Molecular da niversidade do Porto (IPATIMUP) , Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal
| | - J Ribeiro
- Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal. ; Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA) , Rua D. Manuel II, Apartado 55142, 4051-401, Porto, Portugal. ; UPVET, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
| | - Jd Santos
- CEMUC, Departamento de Engenharia Metalúrgica e Materiais, Faculdade de Engenharia , Universidade do Porto, Rua Dr Roberto Frias, 4200-465 Porto, Portugal
| | - Rn Bárcia
- ECBio - Research and Development in Biotechnology S.A. , Rua Henrique Paiva Couceiro, 27, 2700-451 Amadora, Portugal
| | - P Cruz
- ECBio - Research and Development in Biotechnology S.A. , Rua Henrique Paiva Couceiro, 27, 2700-451 Amadora, Portugal
| | - H Cruz
- ECBio - Research and Development in Biotechnology S.A. , Rua Henrique Paiva Couceiro, 27, 2700-451 Amadora, Portugal
| | - Al Luís
- Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal. ; Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal
| | - Jm Santos
- ECBio - Research and Development in Biotechnology S.A. , Rua Henrique Paiva Couceiro, 27, 2700-451 Amadora, Portugal
| | - S Geuna
- Neuroscience Institute of the Cavalieri Ottolenghi Foundation , Turin, Italy. ; Department of Clinical and Biological Sciences , University of Turin, Italy
| | - Ac Maurício
- Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS) , Universidade do Porto (UP), Rua de Jorge Viterbo Ferreira, nº 228, 4050-313 Porto, Portugal. ; Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA) , Rua D. Manuel II, Apartado 55142, 4051-401, Porto, Portugal
| |
Collapse
|
49
|
Abstract
While waste is increasingly viewed as a resource to be globally traded, increased regulatory control on waste across Europe has created the conditions where waste crime now operates alongside a legitimate waste sector. Waste crime,is an environmental crime and a form of white-collar crime, which exploits the physical characteristics of waste, the complexity of the collection and downstream infrastructure, and the market opportunities for profit. This paper highlights some of the factors which make the waste sector vulnerable to waste crime. These factors include new legislation and its weak regulatory enforcement, the economics of waste treatment, where legal and safe treatment of waste can be more expensive than illegal operations, the complexity of the waste sector and the different actors who can have some involvement, directly or indirectly, in the movement of illegal wastes, and finally that waste can be hidden or disguised and creates an opportunity for illegal businesses to operate alongside legitimate waste operators. The study also considers waste crime from the perspective of particular waste streams that are often associated with illegal shipment or through illegal treatment and disposal. For each, the nature of the crime which occurs is shown to differ, but for each, vulnerabilities to waste crime are evident. The paper also describes some approaches which can be adopted by regulators and those involved in developing new legislation for identifying where opportunities for waste crime occurs and how to prevent it.
Collapse
Affiliation(s)
- J Baird
- 1School of Engineering and the Built Environment, Glasgow Caledonian University, Glasgow, UK
| | | | | |
Collapse
|
50
|
Abstract
INTRODUCTION Induction therapy reduces rejection episodes among patients at high immunologic risk. Antithymocyte globulins appear to be superior to basiliximab in this population, despite the greater potential risk of infection and neoplasia. The aim of this study was to evaluate graft function and acute rejection episodes in 6 HLA-mismatched patients who underwent induction with basiliximab but had no other immunologic risk factors. METHODS We analyzed retrospectively patients who were transplanted using basiliximab for induction therapy during a 4 year period, comparing patients with full HLA mismatches with those who had 5 or fewer mismatches. None of the patients had other immunological risk factors for rejection. RESULTS We observed no significant differences between the groups concerning demographic features, cold ischemia times, and panel reactive antibodies. Graft function at 12 and 24 months was not different between both groups. Acute rejection episodes were also not different between groups. DISCUSSION In this population of full HLA mismatches and no other immunological risk factors, induction immunosuppression therapy with basiliximab was safe in terms of graft function and acute rejection episodes.
Collapse
|